NCT05723549View on ClinicalTrials.gov

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

March 20, 2023

Study Completion Date

March 20, 2023

Conditions
Healthy
Interventions
DRUG

HCP1803-3

Take it once per period

DRUG

RLD2002

Take it once per period

DRUG

HCP1904-1

Take it once per period

Trial Locations (1)

Unknown

Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05723549 - A Study to Evaluate the PK, Safety and Tolerability of HCP1803. | Biotech Hunter | Biotech Hunter